Get started

Financials · ENSC

Ensysce Biosciences Inc. (ENSC) financials

For the twelve months ended Jun 30, 2026, Ensysce Biosciences Inc. reported $4.50M of revenue and -$12.62M of net income.

Revenue, TTM
$4.50M
Revenue growth, YoY
-39.3%
Net income, TTM
-$12.62M
Net margin
-280.5%
Cash
$676.7K
Total debt
$196.8K
P/S
1.55
Market cap
$7.0M
Annual revenue$5.07M
FY2020FY2025
Annual net income-$10.18M
FY2018FY2025

ENSC revenue and earnings growth

ENSC revenueQ2 2026$1.16M

Quarter YoY
-15.1%
QoQ
+21.2%
FY YoY
-2.8%
5Y CAGR
+5.2%

ENSC revenue was $1.16M in fiscal Q2 2026 (ended Jun 30, 2026), down 15.1% from a year earlier and up 21.2% from the prior quarter. For the full fiscal 2025 it was $5.07M, down 2.8% from fiscal 2024. Compound annual growth was +5.2% over 5 years. It rose in 1 of the last 5 fiscal years.

ENSC net incomeQ2 2026-$2.57M

ENSC net income was -$2.57M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.73M a year earlier. For the full fiscal 2025 it was -$10.18M, compared with -$7.99M in fiscal 2024.

ENSC EPSQ2 2026-$0.20

ENSC diluted EPS was -$0.20 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$3.98.

ENSC free cash flowQ4 2025-$1.53M

ENSC free cash flow was -$1.53M in fiscal Q4 2025 (ended Dec 31, 2025). For the full fiscal 2025 it was -$7.93M.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Revenue$5.07M$5.21M$2.23M$2.52M$3.53M$3.93M--
Research and development$10.38M$7.22M$7.59M$19.84M$4.69M$4.39M--
Selling, general and admin$4.93M$4.72M$5.36M$6.91M$18.71M$1.15M--
Operating income-$10.24M-$6.73M-$10.72M-$24.22M-$19.87M-$1.61M-$3.33M-$959.2K
Interest expense$18.8K$1.29M$353.9K$109.5K$1.30M$995.5K--
Pre-tax income-----$4.56M-$512.1K$2.68M
Income tax-----$244.5K$555.2K$553.9K
Net income-$10.18M-$7.99M-$10.63M-$25.09M-$29.89M$56.8K-$1.07M$2.05M
EPS, basic-$3.98-$11.45-$70.40-$2091.30-$444.60$0.00-$9.45-$3.15
EPS, diluted-$3.98-$11.45-$70.40-$2091.30-$22.20$0.00-$9.45-$3.15
Diluted shares2.6M697,686150,93711,9951.3M1.1M441,419.533439,801.4

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Cash and equivalents$4.31M$3.50M$1.12M$3.15M$12.26M$194.2K$1.06M$1.66M
Current assets$7.25M$5.34M$2.29M$5.30M$15.66M$347.9K$1.20M$1.92M
Total assets$7.45M$5.60M$2.71M$5.89M$16.42M$351.8K$196.51M$204.83M
Current liabilities$4.57M$2.21M$3.33M$9.46M$16.48M$7.01M$2.77M$437.9K
Long-term debt-----$225.0K--
Total debt$306.7K$301.7K$854.7K$4.41M$17.19M$225.0K$566.3K-
Total liabilities$4.57M$2.22M$3.36M$9.91M$24.58M$7.01M$17.50M$13.17M
Shareholders' equity$3.21M$3.38M-$651.3K-$4.03M-$8.16M-$6.66M-$6.68M$5.00M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Operating cash flow-$7.81M-$7.50M-$10.78M-$17.89M-$8.24M-$1.25M-$1.42M-$1.24M
Capital expenditures$123.6K-------
Free cash flow-$7.93M-------
Investing cash flow-$123.6K--$4.5K-$183.40M$11.85M$838.6K
Financing cash flow$8.74M$9.88M$8.76M$8.77M$20.31M$1.10M-$11.03M-$32.0K
Share repurchases-----$184.78M$11.58M-
Stock-based compensation$177.1K$110.7K$879.2K$1.07M$121.8K$178.7K--

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Revenue growth, YoY-2.8%133.6%-11.6%-28.5%-10.2%---
Operating margin-202.1%-129.2%-480.5%-959.9%-562.7%-41.0%--
Net margin-200.8%-153.3%-476.4%-994.1%-846.4%1.4%--
Free cash flow margin-156.5%-------
Return on equity-316.6%-236.3%-----41.1%
Return on assets-136.5%-142.7%-392.4%-426.3%-182.0%16.1%-0.5%1.0%
Current ratio1.592.420.690.560.950.050.434.38
Debt to equity0.100.09------

Source: XBRL data Ensysce Biosciences Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-15, first reported Mar 10, 2025.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ENSC peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ENSC$4.50M-39.3%-$12.62M-280.5%$7.0M
COLL$815.19M+7.7%$38.17M4.7%$767.9M

ENSC FAQ

6 questions
  • What is ENSC revenue?
    Ensysce Biosciences Inc. (ENSC) reported $4.50M of revenue for the twelve months ended Jun 30, 2026. That is down 39.3% from the year before. Revenue for fiscal 2025 was $5.07M.
  • Is ENSC profitable?
    No. Ensysce Biosciences Inc. reported a net loss of $12.62M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does ENSC have?
    Ensysce Biosciences Inc. reported $676.7K in cash and cash equivalents and $196.8K of debt on its most recent balance sheet in SEC filings.
  • How fast is ENSC revenue growing?
    Ensysce Biosciences Inc.'s revenue changed -2.8% in fiscal 2025, to $5.07M. Its compound annual growth rate was +5.2% over 5 years.
  • When did ENSC last report financial results?
    The latest statements here come from Ensysce Biosciences Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this ENSC financial data come from?
    Quantisnow builds these statements from the structured XBRL data Ensysce Biosciences Inc. files with the SEC. It is provided for information only and is not investment advice.